We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+11.22%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.92B
AUM Growth
-$861M
(-31%)
Cap. Flow
-$1.08B
Cap. Flow
% of AUM
-56.34%
Top 10 Holdings %
Top 10 Hldgs %
24.9%
Holding
1,961
New
419
Increased
272
Reduced
381
Closed
669
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
KE Holdings
BEKE
|
+$13.6M |
| 2 |
TSMC
TSM
|
+$11.4M |
| 3 |
iShares Russell 2000 ETF
IWM
|
+$11.3M |
| 4 |
Applied Materials
AMAT
|
+$9.44M |
| 5 |
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
|
+$6.99M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KAHC
KKR Acquisition Holdings I Corp.
KAHC
|
+$30.7M |
| 2 |
TWTR
Twitter, Inc.
TWTR
|
+$30.3M |
| 3 |
Y
Alleghany Corp
Y
|
+$24.9M |
| 4 |
CTXS
Citrix Systems Inc
CTXS
|
+$17M |
| 5 |
ZEN
ZENDESK INC
ZEN
|
+$15.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 17.05% |
| 2 | Technology | 12.34% |
| 3 | Consumer Discretionary | 8.56% |
| 4 | Industrials | 7.99% |
| 5 | Healthcare | 7.29% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
976
Maravai LifeSciences
MRVI
$904M
| $178K | 0.01% |
+12,468
| New | +$196K |
|
977
BridgeBio Pharma
BBIO
$16.6B
| $178K | 0.01% |
+23,401
| New | +$224K |
|
|
OIIM
978
DELISTED
02Micro International
OIIM
| $178K | 0.01% |
+39,844
| New | +$173K |
|
979
Vanda Pharmaceuticals
VNDA
$304M
| $176K | 0.01% |
+23,776
| New | +$232K |
|
980
Adaptive Biotechnologies
ADPT
$4.05B
| $173K | 0.01% |
22,678
-80,138
| -78% | -$623K |
|
981
Interface
TILE
$2.18B
| $173K | 0.01% |
+17,510
| New | +$184K |
|
982
Direxion Daily S&P Biotech Bear 3X ETF
LABD
$39.4M
| $173K | 0.01% |
+1,000
| New | +$205K |
|
983
Hudbay
HBM
$12.4B
| $172K | 0.01% |
+34,095
| New | +$164K |
|
984
Acco Brands
ACCO
$402M
| $170K | 0.01% |
30,400
+400
| +1% | +$2.08K |
|
|
OPA
985
DELISTED
Magnum Opus Acquisition Limited
OPA
| $169K | 0.01% |
16,800
| – | – |
|
986
FerroAtlántica
GSM
$865M
| $169K | 0.01% |
43,984
+21,698
| +97% | +$108K |
|
987
CALL
NIO
NIO
$12.1B
| $169K | 0.01% |
17,300
-2,800
| -14% | -$32.3K |
|
988
Roivant Sciences
ROIV
$25.8B
| $169K | 0.01% |
+21,100
| New | +$117K |
|
989
The Honest Company
HNST
$561M
| $167K | 0.01% |
55,449
-9,568
| -15% | -$29.8K |
|
990
JetBlue
JBLU
$2.13B
| $160K | 0.01% |
24,619
+9,619
| +64% | +$70.3K |
|
991
Sutro Biopharma
STRO
$423M
| $156K | 0.01% |
+1,926
| New | +$134K |
|
|
LOKM
992
DELISTED
Live Oak Mobility Acquisition Corp.
LOKM
| $155K | 0.01% |
+15,416
| New | +$153K |
|
993
FTC Solar
FTCI
$46.8M
| $153K | 0.01% |
+5,711
| New | +$135K |
|
994
Tencent Music
TME
$16.2B
| $152K | 0.01% |
+18,300
| New | +$103K |
|
995
Ecovyst
ECVT
$1.1B
| $150K | 0.01% |
+16,919
| New | +$156K |
|
996
Liquidia Corp
LQDA
$8.1B
| $148K | 0.01% |
23,201
-52,227
| -69% | -$281K |
|
997
TETRA Technologies
TTI
$1.28B
| $148K | 0.01% |
42,659
-74,137
| -63% | -$288K |
|
998
Nuvation Bio
NUVB
$2.32B
| $146K | 0.01% |
76,204
+23,500
| +45% | +$47.5K |
|
999
CALL
Paysafe
PSFE
$366M
| $144K | 0.01% |
10,400
+9,508
| +1,066% | +$154K |
|
1000
Vuzix
VUZI
$217M
| $143K | 0.01% |
39,286
+18,869
| +92% | +$86.3K |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q4 2022 Portfolio in Review
As of Q4 2022, Prelude Capital Management held 1,961 positions worth $1.92B, down 31% from $2.79B the previous quarter. Its ten largest holdings account for 25% of the portfolio.
Prelude Capital Management withdrew a net $1.08B in Q4 2022, closing 669 positions and reducing 381 holdings. Its most notable exit was KKR Acquisition Holdings I Corp., an estimated $30.7M position sold in full.
By sector, the portfolio is most concentrated in Financials at 17% of assets, down from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Prelude Capital Management opened a new position in AVEO Pharmaceuticals, Inc. worth $7.55M.
- Prelude Capital Management's largest Q4 2022 buy was AVEO Pharmaceuticals, Inc.: 504,972 shares worth $7.55M.
- Prelude Capital Management added most to KE Holdings in Q4 2022, an estimated $13.6M increase.
- Prelude Capital Management's biggest Q4 2022 reduction was Alphabet (Google) Class A, cutting an estimated $6.9M.
- Prelude Capital Management fully exited KKR Acquisition Holdings I Corp. in Q4 2022, selling an estimated $30.7M.
- Prelude Capital Management's ten largest holdings make up 25% of its $1.92B portfolio in Q4 2022.
- Prelude Capital Management opened 419 new positions and closed 669 in Q4 2022.
- Prelude Capital Management's portfolio value fell 31% quarter-over-quarter to $1.92B.
Based on Prelude Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.